Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (5): 135-141.doi: 10.6040/j.issn.1673-3770.0.2022.214

• Review • Previous Articles     Next Articles

Advances in anti-PD-L1/PD-1 therapy and non-coding RNA regulation in nasopharyngeal carcinoma

TU Qiaoling1, LI Yufeng2, PENG Jun3   

  1. 1. Graduate School, North China University of Science and Technology, Tangshan 063200, Hebei, China2. Central Laboratory, Tangshan People's Hospital, Tangshan 063000, Hebei, China3. Department of Otorhinolaryngology & Head and Neck Surgery, Tangshan People's Hospital, Tangshan 063000, Hebei, China
  • Published:2023-10-13

PDF (PC)

229

Abstract: Nasopharyngeal carcinoma(NPC)is a malignant head and neck tumor type derived from nasopharyngeal epithelium. Successful treatment of patients with advanced or recurrent NPC remains difficult. Recent studies have shown that immunotherapy is effective for these patients. Programmed death ligand 1(PD-L1)is highly expressed in NPC. PD-L1 binding to programmed death receptor 1(PD-1)on the surface of T cells can inhibit T cell activation, leading to immune escape by NPC. Non-coding RNA plays important roles in regulating the occurrence and development of NPC. Searching for upstream ncRNAs that can regulate the PD-L1/PD-1 axis can provide new ideas for immunotherapy of NPC. This article reviews the role of the PD-L1/PD-1 axis in NPC immunotherapy and summarizes progress of research related to ncRNA regulation.

Key words: Nasopharyngeal carcinoma, Programmed death ligand 1/ programmed death receptor 1, Non-coding RNA, Immunotherapy, Molecular mechanism

CLC Number: 

  • R739.6
[1] 方三高, 魏建国, 周晓军. 解读WHO(2017)头颈部肿瘤分类(鼻腔、鼻窦、颅底)[J]. 诊断病理学杂志, 2018, 25(4): 241-245. doi:10.3969/j.issn.1007-8096.2018.04.001
[2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi:10.3322/caac.21660
[3] Chang ET, Ye W, Zeng YX, et al. The evolving epidemiology of nasopharyngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2021, 30(6): 1035-1047. doi:10.1158/1055-9965.EPI-20-1702
[4] Kuang-Rong Wei, Rong-Shou Zheng, Si-Wei Zhang, 等. 2013年中国鼻咽癌发病和死亡分析[J]. 癌症, 2018, 37(4): 170-178
[5] Chen YP, Chan ATC, Le QT, et al. Nasopharyngeal carcinoma[J]. Lancet, 2019, 394(10192): 64-80. doi:10.1016/S0140-6736(19)30956-0
[6] Perri F, Della Vittoria Scarpati G, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives[J]. Onco Targets Ther, 2019, 12: 1583-1591. doi:10.2147/OTT.S188148
[7] Lee AWM, Ng WT, Chan JYW, et al. Management of locally recurrent nasopharyngeal carcinoma[J]. Cancer Treat Rev, 2019, 79: 101890. doi:10.1016/j.ctrv.2019.101890
[8] Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma[J]. N Engl J Med, 2019, 381(12): 1124-1135. doi:10.1056/NEJMoa1905287
[9] Lv JW, Li JY, Luo LN, et al. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials[J]. J Immunother Cancer, 2019, 7(1): 159. doi:10.1186/s40425-019-0636-7
[10] Chow JC, Ngan RK, Cheung KM, et al. Immunotherapeutic approaches in nasopharyngeal carcinoma[J]. Expert Opin Biol Ther, 2019, 19(11): 1165-1172. doi:10.1080/14712598.2019.1650910
[11] Guo Z, Wang YH, Xu H, et al. LncRNA linc00312 suppresses radiotherapy resistance by targeting DNA-PKcs and impairing DNA damage repair in nasopharyngeal carcinoma[J]. Cell Death Dis, 2021, 12(1): 69. doi:10.1038/s41419-020-03302-2
[12] Hong X, Liu N, Liang Y, et al. Circular RNA CRIM1 functions as a ceRNA to promote nasopharyngeal carcinoma metastasis and docetaxel chemoresistance through upregulating FOXQ1[J]. Mol Cancer, 2020, 19(1): 33. doi:10.1186/s12943-020-01149-x
[13] Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol, 2015, 16(6): 645-655. doi:10.1016/S1470-2045(15)70126-9
[14] Yang P, Zhou T, Chen X, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma(CAPTAIN study)[J]. J Immunother Cancer, 2021, 9(12): e003790. doi:10.1136/jitc-2021-003790
[15] Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 expression and CD8+ tumor-infiltrating lymphocyte in Epstein-Barr virus-associated nasopharyngeal carcinoma[J]. Am J Clin Oncol, 2018, 41(12): 1204-1210. doi:10.1097/COC.0000000000000449
[16] Lau KM, Cheng SH, Lo KW, et al. Increase in circulating Foxp3+CD4+CD25(high)regulatory T cells in nasopharyngeal carcinoma patients[J]. Br J Cancer, 2007, 96(4): 617-622. doi:10.1038/sj.bjc.6603580
[17] Ding L, Lu S, Li Y. Regulation of PD-1/PD-L1 pathway in cancer by noncoding RNAs[J]. Pathol Oncol Res, 2020, 26(2): 651-663. doi:10.1007/s12253-019-00735-9
[18] Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J]. Annu Rev Immunol, 2008, 26: 677-704. doi:10.1146/annurev.immunol.26.021607.090331
[19] Dong HD, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800. doi:10.1038/nm730
[20] Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint[J]. Immunity, 2018, 48(3): 434-452. doi:10.1016/j.immuni.2018.03.014
[21] Zhao R, Song Y, Wang Y, et al. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway[J]. Cell Prolif, 2019, 52(3): e12571. doi:10.1111/cpr.12571
[22] Piao W, Li L, Saxena V, et al. PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration[J]. Nat Commun, 2022, 13(1): 2176. doi:10.1038/s41467-022-29930-0
[23] Wang YQ, Zhang Y, Jiang W, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis[J]. J Immunother Cancer, 2019, 7(1): 298. doi:10.1186/s40425-019-0752-4
[24] Fang W, Yang Y, Ma Y, et al. Camrelizumab(SHR-1210)alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol, 2018, 19(10): 1338-1350. doi:10.1016/S1470-2045(18)30495-9
[25] Ma BBY, Lim WT, Goh BC, et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium(NCI-9742)[J]. J Clin Oncol, 2018, 36(14): 1412-1418. doi:10.1200/JCO.2017.77.0388
[26] Even C, Wang HM, Li SH, et al. Phase II, randomized study of spartalizumab(PDR001), an anti-PD-1 antibody, versus chemotherapy in patients with recurrent/metastatic nasopharyngeal cancer[J]. Clin Cancer Res, 2021, 27(23): 6413-6423. doi:10.1158/1078-0432.CCR-21-0822
[27] Wang FH, Wei XL, Feng J, et al. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial(POLARIS-02)[J]. J Clin Oncol, 2021, 39(7): 704-712. doi:10.1200/JCO.20.02712
[28] Makowska A, Meier S, Shen L, et al. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1[J]. Cancer Immunol Immunother, 2021, 70(2): 323-336. doi:10.1007/s00262-020-02681-x
[29] Yuan Y, Adam A, Zhao C, et al. Recent advancements in the mechanisms underlying resistance to PD-1/PD-L1 blockade immunotherapy[J]. Cancers(Basel), 2021, 13(4): 663. doi:10.3390/cancers13040663
[30] Zhang P, Wu W, Chen Q, et al. Non-coding RNAs and their integrated networks[J]. J Integr Bioinform, 2019, 16(3): 20190027. doi:10.1515/jib-2019-0027
[31] Mohr AM, Mott JL. Overview of microRNA biology[J]. Semin Liver Dis, 2015, 35(1): 3-11. doi:10.1055/s-0034-1397344
[32] Wu RS, Qiu EH, Zhu JJ, et al. miR-101 promotes nasopharyngeal carcinoma cell apoptosis through inhibiting Ras/Raf/MEK/ERK signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16): 8240. doi:10.26355/eurrev_202008_22580
[33] Liu YL, Yang WH, Chen BY, et al. miR-29b suppresses proliferation and induces apoptosis of hepatocellular carcinoma ascites H22 cells via regulating TGF-β1 and p53 signaling pathway[J]. Int J Mol Med, 2021, 48(2): 157. doi:10.3892/ijmm.2021.4990
[34] Kooshkaki O, Rezaei Z, Rahmati M, et al. miR-144: a new possible therapeutic target and diagnostic/prognostic tool in cancers[J]. Int J Mol Sci, 2020, 21(7): E2578. doi:10.3390/ijms21072578
[35] Huang W, Song W, Jiang Y, et al. C-Myc-induced circ-NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the miR-34c-5p/c-Myc axis[J]. Cell Biol Int, 2021, 45(7): 1436-1447. doi:10.1002/cbin.11582
[36] Chen M, Chen C, Luo H, et al. MicroRNA-296-5p inhibits cell metastasis and invasion in nasopharyngeal carcinoma by reversing transforming growth factor-β-induced epithelial-mesenchymal transition[J]. Cell Mol Biol Lett, 2020, 25(1): 49. doi:10.1186/s11658-020-00240-x
[37] Han JB, Huang ML, Li F, et al. MiR-214 mediates cell proliferation and apoptosis of nasopharyngeal carcinoma through targeting both WWOX and PTEN[J]. Cancer Biother Radiopharm, 2020, 35(8): 615-625. doi:10.1089/cbr.2019.2978
[38] Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. PD-1/PD-L1 axis regulation in cancer therapy: the role of long non-coding RNAs and microRNAs[J]. Life Sci, 2020, 256: 117899. doi:10.1016/j.lfs.2020.117899
[39] Zhang Y, Zhu R, Wang J, et al. Upregulation of lncRNA H19 promotes nasopharyngeal carcinoma proliferation and metastasis in let-7 dependent manner[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3854-3861. doi:10.1080/21691401.2019.1669618
[40] Zheng YJ, Zhao JY, Liang TS, et al. Long noncoding RNA SMAD5-AS1 acts as a microRNA-106a-5p sponge to promote epithelial mesenchymal transition in nasopharyngeal carcinoma[J]. FASEB J, 2019, 33(11): 12915-12928. doi:10.1096/fj.201900803R
[41] Zhang W, Guo Q, Liu G, et al. NKILA represses nasopharyngeal carcinoma carcinogenesis and metastasis by NF-κB pathway inhibition[J]. PLoS Genet, 2019, 15(8): e1008325. doi:10.1371/journal.pgen.1008325
[42] Mo Y, Wang Y, Zhang S, et al. Circular RNA circRNF13 inhibits proliferation and metastasis of nasopharyngeal carcinoma via SUMO2[J]. Mol Cancer, 2021, 20(1): 112. doi:10.1186/s12943-021-01409-4
[43] Fan C, Qu H, Xiong F, et al. CircARHGAP12 promotes nasopharyngeal carcinoma migration and invasion via ezrin-mediated cytoskeletal remodeling[J]. Cancer Lett, 2021, 496: 41-56. doi:10.1016/j.canlet.2020.09.006
[44] Yu H, Zhang C, Li W, et al. Nano-coated si-SNHG14 regulated PD-L1 expression and decreased epithelial-mesenchymal transition in nasopharyngeal carcinoma cells[J]. J Biomed Nanotechnol, 2021, 17(10): 1993-2002. doi:10.1166/jbn.2021.3162
[45] Tang Y, He Y, Shi L, et al. Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinoma[J]. Oncotarget, 2017, 8(24): 39001-39011. doi:10.18632/oncotarget.16545
[46] Wang S, You H, Yu S. Long non-coding RNA HOXA-AS2 promotes the expression levels of hypoxia-inducible factor-1α and programmed death-ligand 1, and regulates nasopharyngeal carcinoma progression via miR-519[J]. Oncol Lett, 2020, 20(5): 245. doi:10.3892/ol.2020.12107
[47] Ge J, Wang J, Xiong F, et al. Epstein-Barr virus-encoded circular RNA CircBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1[J]. Cancer Res, 2021, 81(19): 5074-5088. doi:10.1158/0008-5472.CAN-20-4321
[48] Wang J, Ge J, Wang Y, et al. EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1[J]. Nat Commun, 2022, 13(1): 866. doi:10.1038/s41467-022-28479-2
[49] Wu Q, Zhao Y, Sun Y, et al. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling[J]. Oncol Rep, 2018, 39(3): 1461-1468. doi:10.3892/or.2018.6177
[1] LIN Xiaoxue, LIN Baorui, LI Peishan, LU Biaoqing. Application of electronic nasopharyngoscopy combined with narrow band imaging in traditional Chinese medicine syndrome differentiation of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(3): 40-46.
[2] GU Min, LU Meiping. Advances in the application of nanomedicine delivery systems in allergen immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 106-111.
[3] PAN Linlin, WAN Jiaming, LI Yue, HE Long. Autophagy-related long noncoding RNA is a prognostic indicator for head and neck squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(6): 97-107.
[4] XU Xuemeng, FAN Lei, YU Wangbo, JIANG Zhiyue, PAN Chen, HUANG Yongqin. Meta-analysis of the efficacy of omalizumab in combination with specific immunotherapy for allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 26-33.
[5] WANG Sheng, LI Yindan, YANG Jinji. The role of microRNA in nasopharyngeal carcinoma and its research progress [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 125-131.
[6] ZHANG Ting, WANG Meilan, GAO Yingqin. Research progress of IL-35 in allergic rhinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(5): 139-147.
[7] QIU Qianhui, XIAO Xuping, YANG Qintai, YE Jing, DENG Zeyi, WANG Desheng, TAN Guolin, JIANG weihong,. Expert consensus on clinical management recommendations for carotid blowout syndrome secondary to NPC treatment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 1-18.
[8] WANG Siquan, ZHU Hongshen, ZHANG Xiaobin, ZHAO Zhouyang, MA Yue, YANG Yimei, HUANG Lijin. Analysis of factors associated with stroke and cranial nerve palsy after unilateral internal carotid artery embolization in patients with nasopharyngeal carcinoma after radiotherapy [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 19-25.
[9] HUANG Qiao, REN Yi, HOU Tao, LIAO Xingwei, ZHU Zi’ang, ZHAN Xiaolin, LIU Ying, YIN Shihua. Expression of EphB2 in nasopharyngeal carcinoma tissues and its correlation with clinicopathological characteristics [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 26-30.
[10] SUN Chunxiao, WANG Wenqing, YUE Tian, LIU Jisheng. Efficacy analysis of concurrent chemoradiotherapy with high and low cumulative cisplatin doses in the treatment of nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 31-41.
[11] WANG Zaixing, TANG Zhiyuan, LI Dingbo, SHI Zhaohui, ZENG Xianhai, ZHANG Qiuhang. Treatment of internal carotid artery rupture caused by tumor recurrence and skull base osteonecrosis after radiotherapy for nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 49-58.
[12] SUN Fang, XIE Chubo, QIU Qianhui. Retrospective analysis of nutritional indexes and their impact on wound healing in patients with radiation-induced skull base osteoradionecrosis after treatment with nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 59-68.
[13] ZHU Ruikai, WU Jiarong, SUN Fang, XIE Chubo, QIU Qianhui. Computed tomography angiography-based assessment of internal carotid artery stenosis after radiotherapy for nasopharyngeal carcinoma and its associated factors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 77-84.
[14] QIN Debo, XUE Jiancheng, YANG Wenyue, HU Bing, CHEN Tao, YU Yanping, MENG Qingguo, SUN Huanji, MIAO Beiping, LU Yongtian. Changing the diagnosis and treatment of nasopharyngeal cancer: biomarkers and nasal endoscopic surgery synergise to advance early treatment development [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 85-92.
[15] WU Jiarong, QIU Qianhui. The role and significance of the skull base fascial tissue barrier in endoscopic resection of locally early recurrent nasopharyngeal carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 108-113.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd